Viewing nowIrostar Tablets (Rosuvastatin Calcium)
Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
IYun Pharmaceuticals Co., Ltd.

MFDS item code 201404145 · Approved 2014.09.05 · Insurance code 658603090
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
This drug is used adjunctively in patients with primary hypercholesterolemia and mixed dyslipidemia who are not adequately controlled with diet and exercise. It is also used as an adjunct to dietary therapy or other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia, lowering total cholesterol and LDL-cholesterol levels to delay the progression of atherosclerosis. It is indicated for pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia who have elevated LDL-cholesterol levels or risk factors for cardiovascular disease. It is also effective as an adjunct to dietary therapy in patients with primary dysbetalipoproteinemia and helps reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults at high risk for cardiovascular disease. Overall, this drug improves blood lipid levels and reduces the risk of cardiovascular disease.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this drug should follow a standard cholesterol-lowering diet before and during treatment. This drug may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Older adults: Dose adjustment is not necessary. 4. Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this drug 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
2. Pediatric patients with heterozygous familial hypercholesterolemia (age 10 to 17 years) The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.
This drug is contraindicated in certain patients. It should not be administered to patients with a history of allergy to this drug, severe hepatic impairment, or muscle disease. Additionally, it should not be used in patients with significantly impaired renal function, pregnant or breastfeeding women, or women of childbearing age who are not using adequate contraception. High-dose administration is prohibited in patients at high risk for muscle disease. This drug contains lactose; therefore, patients with lactose intolerance or certain genetic disorders should avoid it. Caution is particularly necessary for patients with impaired liver function, those who consume a significant amount of alcohol, or those with hypothyroidism. If symptoms such as muscle pain or weakness appear, the doctor must be notified immediately, and blood tests should be conducted to check for muscle damage if necessary. This drug should be discontinued if acute severe illness or severe muscle weakness occurs. Because this drug may affect the liver and kidneys, regular monitoring is necessary, especially with high-dose administration. Asian patients may exhibit higher drug concentrations, requiring dose adjustments. Serious adverse reactions such as severe skin reactions, liver damage, or muscle diseases can occur during treatment; thus, any abnormal symptoms should be reported to healthcare professionals immediately. When taken with other medications, interactions may occur; therefore, patients must inform their healthcare providers about all current medications, and there is an increased risk of muscle disease with certain drug combinations. Pregnant or breastfeeding women should not use this drug, and women of childbearing age should ensure adequate contraception. In cases of overdose, there is no specific antidote; treatment should be symptomatic, and liver and muscle function tests are necessary. This drug does not appear to significantly affect driving or operating machinery, but caution is warranted as dizziness may occur. Lastly, this drug may rarely cause interstitial lung disease with long-term use; therefore, treatment should be discontinued, and healthcare providers should be consulted immediately if any unusual symptoms arise.
Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and drug reaction with systemic symptoms, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius.
Pink round film-coated tablets
28 tablets/PTP (14 tablets/PTP × 2), 30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 10.4mg
Tablet · Prescription medication
IYun Pharmaceuticals Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.